CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
Information source: Nabi Biopharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Calcinosis; Arteriosclerosis; Hyperparathyroidism, Secondary
Intervention: calcium acetate (Drug); sevelamer (Drug); atorvastatin (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Nabi Biopharmaceuticals Official(s) and/or principal investigator(s): Wajeh Y Qunibi, M.D., Study Chair, Affiliation: The University of Texas Health Science Center at San Antonio
Summary
The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and
sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive
technique, electron beam computed tomography (CT) scanning, to measure calcium in the
coronary arteries, the aortic valve, and the mitral valve.
Clinical Details
Official title: CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2)
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: electron-beam CT coronary artery calcification AGATSTON score
Secondary outcome: serum phosphoruscalcium x phosphorus product
Detailed description:
Cardiovascular disease is the major cause of death and disability in patients with end-stage
renal disease on hemodialysis. It has been hypothesized that ingestion of calcium-based
phosphate binders results in net positive calcium balance and vascular calcium deposition.
Chertow et al. tested the role of ingested calcium in the progression of cardiovascular
calcification in the Treat-To-Goal study (Kidney International 62: 245, 2002). They reported
that patients treated with calcium-based phosphate binders demonstrated progressive
cardiovascular calcification, while patients treated with a calcium-free binder, sevelamer,
showed stabilization or improvement in calcification scores. However, the protocol did not
prohibit intake of supplemental oral calcium in the sevelamer group, which confounded their
ability to accurately test the calcium hypothesis. Moreover, due to the cholesterol
sequestering activities of sevelamer, the low-density lipoprotein (LDL) cholesterol was
lower among sevelamer-treated patients than the calcium treated patients, resulting in a
major imbalance in a cardiovascular risk factor. Lowering LDL level reduces progression of
CVC and therefore confounds interpretation of the study. Subsequently, it has been reported
in the lay press that patients randomized to sevelamer or calcium-based binders in the
Dialysis Clinical Outcomes Revisited (DCOR) study have failed to show a difference in
mortality or major secondary endpoints (Suki et al., To be presented American Society of
Nephrology November 2005). To circumvent these limitations, the CARE-2 study will test the
hypothesis that if LDL levels are lowered to a similar level in calcium acetate and
sevelamer-treated patients, there will be no difference in the progression of cardiac
calcification. CARE-2 will randomize patients with elevated LDL to calcium acetate or
sevelamer. Atorvastatin is added to achieve LDL < 70 mg/dL in both treatment groups. The
primary endpoint is change in cardiac calcification scores, determined by electron beam
scanning after 1 year. Secondary endpoints include the ability of calcium acetate and
sevelamer to control phosphorus and meet NKF-K/DOQI guidelines.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Eligible subjects will be male or female patients with end-stage renal disease on
maintenance hemodialysis for less than 5 years, with elevated LDL cholesterol
- Currently treated with oral phosphate binders
- Coronary artery calcium scores of 30 to 5000 Agatston units measured by electron beam
CT scanning
- Written informed consent
- Negative serum pregnancy test if appropriate
- Expect to comply with protocol procedures and schedule
Exclusion Criteria:
- Unstable angina pectoris
- Severe congestive heart failure
- Severe obstructive pulmonary disease requiring supplemental oxygen
- Severe liver dysfunction
- Severe malnutrition
- Severe hyperparathyroidism
- Known HIV
- Active malignancy for which the subject is receiving chemotherapy or radiation
- Planned renal transplant within the next year
- Clinical evidence of calciphylaxis or recent history of hypercalcemia
- History of obstructed bowels
- Hypersensitivity to any of the components of the study medication
- History of swallowing disorders
- Weight > 300 pounds
- Any condition which makes patient participation not in the patient's best interest
Locations and Contacts
University of Texas Health Sciences Center, San Antonio, Texas 78229-3900, United States
Additional Information
Related publications: Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002 Jul;62(1):245-52.
Starting date: January 2005
Last updated: December 26, 2007
|